Tucidinostat

Phase 3Small molecule

CChipscreen Biosciences, Ltd.

Tucidinostat is one of 186 small molecule programs targeting First-line Treatment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

185

Competitors

Pipeline

Status by Indication[3][1]

Indication

First-Line TreatmentActive, not recruiting

Newly DiagnosedActive, not recruiting

LymphomaRecruiting

Colorectal CancerRecruiting

First-Line TreatmentPhase 2

Active, not recruiting

Newly DiagnosedPhase 3

Active, not recruiting

LymphomaPhase 3

Recruiting

Colorectal CancerPhase 3

Recruiting

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Tucidinostat

CChipscreen Biosciences, Ltd.

Phase 3

1 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—6

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—8

R-CHOP

IIncyte Biosciences Japan GK

Preclinical

1 9

Immune Checkpoint Inhibitor

IImmuneSensor Therapeutics Inc.

Preclinical

1 10

Antibody-Drug Conjugate

MMBrace Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Colorectal Cancer

NCT06497985

Q4 2032

Phase 3Recruiting

Lymphoma

NCT06947967

Clinical

Trials by Indication[1]

Breast Cancer5 trials

Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer

Completed·FFirst Affiliated Hospital, Sun Yat-Sen University·Phase 2·NCT04465097·30 enrolled

Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor

Unknown status·—··NCT05276713·50 enrolled

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Unknown status·Wwang shusen·Phase 2·NCT05411380·73 enrolled

Show 2 more trials

Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer

Unknown status·GGuangdong Women and Children Hospital·Phase 2·NCT04999540·73 enrolled

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

Unknown status·HHunan Cancer Hospital·Phase 2·NCT05633914·90 enrolled

Lymphoma1 trial

Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Recruiting·CChipscreen Biosciences, Ltd.·Phase 3·NCT06947967·224 enrolled

Newly Diagnosed1 trial

Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL

Active, not recruiting·CChipscreen Biosciences, Ltd.·Phase 3·NCT04231448·423 enrolled

Triple-Negative Breast Cancer1 trial

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

Unknown status·Wwang shusen·Phase 2·NCT05390476·126 enrolled

PTCL1 trial

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Unknown status·RRuijin Hospital·Phase 1/2·NCT05559008·116 enrolled

3 more indications

Colorectal Cancer1 trial

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Recruiting·CChipscreen Biosciences, Ltd.·Phase 3·NCT06497985·430 enrolled

First-line Treatment1 trial

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

Active, not recruiting·CChipscreen Biosciences, Ltd.·Phase 2·NCT05519865·118 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma

Completed·OOu Bai, MD/PHD·Phase 2·NCT04661943·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Tucidinostat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tucidinostat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tucidinostat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chipscreen Biosciences, Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CChipscreen Biosciences, Ltd.

Tucidinostat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2032

Trials by Indication[1]

Breast Cancer5 trials

Lymphoma1 trial

Newly Diagnosed1 trial

Triple-Negative Breast Cancer1 trial

PTCL1 trial

Colorectal Cancer1 trial

First-line Treatment1 trial

Diffuse Large B-Cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News